New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: Clinical, Parasitological, and Serological Assessment after Three Years of Follow-Up.
Chagas disease
Trypanosoma cruzi
benznidazole
chronic infection
intermittent treatment
Journal
Antimicrobial agents and chemotherapy
ISSN: 1098-6596
Titre abrégé: Antimicrob Agents Chemother
Pays: United States
ID NLM: 0315061
Informations de publication
Date de publication:
20 08 2020
20 08 2020
Historique:
received:
12
03
2020
accepted:
18
06
2020
pubmed:
24
6
2020
medline:
22
6
2021
entrez:
24
6
2020
Statut:
epublish
Résumé
In a pilot study, we showed that the intermittent administration of benznidazole in chronic Chagas disease patients resulted in a low rate of treatment suspension and therapeutic failure, as assessed by quantitative PCR (qPCR) at the end of treatment. Here, a 3-year posttreatment follow-up study of the same cohort of patients is presented. The treatment scheme consisted of 12 doses of benznidazole at 5 mg/kg of body weight/day in two daily doses every 5 days. Parasite load,
Identifiants
pubmed: 32571827
pii: AAC.00439-20
doi: 10.1128/AAC.00439-20
pmc: PMC7449225
pii:
doi:
Substances chimiques
Nitroimidazoles
0
Trypanocidal Agents
0
benzonidazole
YC42NRJ1ZD
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2020 American Society for Microbiology.
Références
Parasite Immunol. 2013 May-Jun;35(5-6):180-7
pubmed: 23473453
PLoS Negl Trop Dis. 2016 Apr 29;10(4):e0004657
pubmed: 27128444
Rev Inst Med Trop Sao Paulo. 2000 Mar-Apr;42(2):99-109
pubmed: 10810325
Eur J Clin Microbiol Infect Dis. 2016 Nov;35(11):1819-1827
pubmed: 27488437
Antimicrob Agents Chemother. 2015 Nov 23;60(2):833-7
pubmed: 26596935
J Antimicrob Chemother. 2013 Feb;68(2):424-37
pubmed: 23104493
Immunol Cell Biol. 2011 Feb;89(2):207-15
pubmed: 21221121
Heart Vessels. 2019 Jan;34(1):123-133
pubmed: 30047012
Clin Infect Dis. 2009 Dec 1;49(11):1675-84
pubmed: 19877967
Clin Chim Acta. 2010 Nov 11;411(21-22):1570-9
pubmed: 20633546
PLoS Negl Trop Dis. 2011 Jan 11;5(1):e931
pubmed: 21264349
Elife. 2018 Mar 26;7:
pubmed: 29578409
J Mol Diagn. 2015 Sep;17(5):605-15
pubmed: 26320872
Arq Bras Cardiol. 1993 Feb;60(2):71-5
pubmed: 8240052
World Health Organ Tech Rep Ser. 2012;(975):v-xii, 1-100
pubmed: 23484340
J Immunol. 2017 Apr 15;198(8):3170-3180
pubmed: 28258194
PLoS Negl Trop Dis. 2008 Oct 08;2(10):e316
pubmed: 18841200
Eur J Med Chem. 2019 Jan 15;162:378-395
pubmed: 30453246
JAMA. 2007 Nov 14;298(18):2171-81
pubmed: 18000201
N Engl J Med. 2014 May 15;370(20):1899-908
pubmed: 24827034
Antimicrob Agents Chemother. 2015;59(6):3342-9
pubmed: 25824212
Mem Inst Oswaldo Cruz. 2016 Mar;111(3):218-21
pubmed: 26982179
Wkly Epidemiol Rec. 2015 Feb 6;90(6):33-43
pubmed: 25671846
Rev Soc Bras Med Trop. 2009 Nov-Dec;42(6):622-8
pubmed: 20209343
Front Immunol. 2018 Sep 13;9:1958
pubmed: 30271399
J Mol Diagn. 2017 Sep;19(5):673-681
pubmed: 28727985
PLoS One. 2014 Mar 07;9(3):e91154
pubmed: 24608170
Lancet Infect Dis. 2018 Apr;18(4):419-430
pubmed: 29352704
J Am Coll Cardiol. 2017 Feb 28;69(8):939-947
pubmed: 28231946
Expert Rev Anti Infect Ther. 2009 Mar;7(2):157-63
pubmed: 19254164
Trans R Soc Trop Med Hyg. 2012 Oct;106(10):636-8
pubmed: 22898619
PLoS Negl Trop Dis. 2011 Sep;5(9):e1314
pubmed: 21909451
N Engl J Med. 2015 Oct;373(14):1295-306
pubmed: 26323937
Int J Mol Sci. 2018 Oct 18;19(10):
pubmed: 30340330
J Infect Dis. 2014 Jan 1;209(1):150-62
pubmed: 23945371
PLoS Negl Trop Dis. 2014 May 22;8(5):e2907
pubmed: 24853169
Ann Intern Med. 2006 May 16;144(10):724-34
pubmed: 16702588